MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/8/2019 |
| Start Date: | November 2015 |
| End Date: | April 2034 |
| Contact: | Ben Creelan, MD, MS |
| Email: | ben.creelan@moffitt.org |
| Phone: | 813-745-3328 |
A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
This first time in human study is intended for men and women at least 18 years of age who
have advanced lung cancer which has grown or returned after being treated. In particular, it
is a study for subjects who have a blood test positive for HLA-A*02:01 and/or HLA-A*02:06 and
a tumor test positive for MAGE A10 protein expression (protein or gene). This trial is a dose
escalation trial that will evaluate 3 doses of transduced cells administered after a
lymphodepleting chemotherapy regimen using a 3+3 dose escalation design .The study will take
the subject's T cells, which are a natural type of immune cell in the blood, and send them to
a laboratory to be modified. The changed T cells used in this study will be the subject's own
T cells that have been genetically changed with the aim of attacking and destroying cancer
cells.
When the MAGE A10ᶜ⁷⁹⁶T cells are available, subjects will receive lymphodepleting
chemotherapy with cyclophosphamide and fludarabine, followed by the T cell infusion. The
purpose of this study is to test the safety of genetically changed T cells and find out what
effects, if any, they have in subjects with lung cancer. The study will evaluate three
different cell dose levels in order to find out the target cell dose. Once the target cell
dose is determined, additional subjects will be enrolled to further test the safety and
effects at this cell dose.
Subjects will be seen frequently by the Study Physician right after receiving their T cells
back and up to first 6 months. After that, subjects will be seen every three months. Subjects
will be seen every 6 months by their Study Physician for the first 5 years after the T cell
infusion. If the T cells are found in the blood at five years, then the subjects will
continue to be seen once a year until the T cells are no longer found in the blood for a
maximum of 15 years. If the T cells are no longer found in the blood at 5 years, then the
subject will be contacted by the Study Physician for the next 10 years. Subjects who have a
confirmed response (or have stable disease for >4 months) but subsequent disease progression
following the initial infusion and whose tumor continues to express the appropriate antigen
target may be eligible for a second infusion. All subjects, completing or withdrawing from
the Interventional Phase of the study, will enter a 15-year long-term follow-up phase for
observation of delayed adverse events, All subjects will continue to be followed for overall
survival during the long-term follow-up phase.
have advanced lung cancer which has grown or returned after being treated. In particular, it
is a study for subjects who have a blood test positive for HLA-A*02:01 and/or HLA-A*02:06 and
a tumor test positive for MAGE A10 protein expression (protein or gene). This trial is a dose
escalation trial that will evaluate 3 doses of transduced cells administered after a
lymphodepleting chemotherapy regimen using a 3+3 dose escalation design .The study will take
the subject's T cells, which are a natural type of immune cell in the blood, and send them to
a laboratory to be modified. The changed T cells used in this study will be the subject's own
T cells that have been genetically changed with the aim of attacking and destroying cancer
cells.
When the MAGE A10ᶜ⁷⁹⁶T cells are available, subjects will receive lymphodepleting
chemotherapy with cyclophosphamide and fludarabine, followed by the T cell infusion. The
purpose of this study is to test the safety of genetically changed T cells and find out what
effects, if any, they have in subjects with lung cancer. The study will evaluate three
different cell dose levels in order to find out the target cell dose. Once the target cell
dose is determined, additional subjects will be enrolled to further test the safety and
effects at this cell dose.
Subjects will be seen frequently by the Study Physician right after receiving their T cells
back and up to first 6 months. After that, subjects will be seen every three months. Subjects
will be seen every 6 months by their Study Physician for the first 5 years after the T cell
infusion. If the T cells are found in the blood at five years, then the subjects will
continue to be seen once a year until the T cells are no longer found in the blood for a
maximum of 15 years. If the T cells are no longer found in the blood at 5 years, then the
subject will be contacted by the Study Physician for the next 10 years. Subjects who have a
confirmed response (or have stable disease for >4 months) but subsequent disease progression
following the initial infusion and whose tumor continues to express the appropriate antigen
target may be eligible for a second infusion. All subjects, completing or withdrawing from
the Interventional Phase of the study, will enter a 15-year long-term follow-up phase for
observation of delayed adverse events, All subjects will continue to be followed for overall
survival during the long-term follow-up phase.
Key Inclusion Criteria:
1. Subject has histologically or cytologically confirmed diagnosis of advanced non-small
cell lung cancer (stage IIIB or IV) or recurrent disease
2. Subject has received at least one line of prior therapy
3. Subjects with known epidermal growth factor receptor (EGFR) mutations or anaplastic
lymphoma kinase receptor (ALK) or ROS1 gene rearrangements must have failed
(progressive disease or unacceptable toxicity) at least one prior EGFR or ALK or ROS1
tyrosine kinase inhibitor, respectively. Subject may have received PD-1 or PDL-1
inhibitors and or chemotherapy. There is no limit on lines of prior anti-cancer
therapy (a washout period applies for recent anti-cancer treatments).
4. Subject has measurable disease according to RECIST v1.1 criteria prior to
lymphodepletion.
5. Subject is HLA-A*02:01 or HLA-A*02:06 positive.
6. Subject's tumor (either an archival specimen or a fresh biopsy if archival tissue is
unavailable) has been pathologically reviewed by a designated central laboratory
confirming MAGE-A10 expression.
7. Subject has an ECOG Performance Status 0-1 and anticipated life expectancy >6 months
prior to apheresis and >3 months prior to lymphodepletion.
8. Subject is ≥18 years of age
9. Adequate organ function
Key Exclusion Criteria:
1. Subject is HLA-A*02:05, HLA-B*15:01 and/or HLA-B*46:01 positive.
2. History of chronic or recurrent (within the last year prior to enrollment) severe
autoimmune or active immune-mediated disease requiring steroids or other
immunosuppressive treatments.
3. Subject has symptomatic CNS metastases. Subjects with prior history of symptomatic CNS
metastasis must have received treatment and be neurologically stable for at least 1
month prior to leukapheresis and lymphodepletion.
4. Active malignancy besides NSCLC within 3 years prior to screening.
5. Uncontrolled intercurrent illness including, but not limited to:
- Ongoing or active infection;
- Clinically significant cardiac disease
- Inadequate pulmonary function
- Interstitial lung disease
We found this trial at
15
sites
410 W 10th Ave
Columbus, Ohio 43210
Columbus, Ohio 43210
(614) 293-8652
Principal Investigator: Kai He, MD
Phone: 614-685-5414
The Ohio State University, Wexner Medical Center Located in Columbus, The Ohio State University Wexner...
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Justin F Gainor, M.D.
Phone: 617-724-4000
Click here to add this to my saved trials
1365 Clifton Rd NE
Atlanta, Georgia 30322
Atlanta, Georgia 30322
(404) 778-1900
Principal Investigator: Taofeek K Owonikoko, MD, PhD
Phone: 404-778-5157
Winship Cancer Institute at Emory University Winship Cancer Institute of Emory University is Georgia
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
Baltimore, Maryland 21201
410-328-7904
Principal Investigator: Christian Rolfo, MD
Phone: 410-328-6465
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
Click here to add this to my saved trials
Click here to add this to my saved trials
20 Duke Medicine Circle
Durham, North Carolina 27710
Durham, North Carolina 27710
Principal Investigator: Jeffrey M Clarke, MD
Phone: 919-668-1462
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
Houston, Texas 77030
713-792-2121
Principal Investigator: George Blumenschein, MD
Phone: 713-745-0294
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
Click here to add this to my saved trials
Indianapolis, Indiana 46202
Principal Investigator: Shadia I Jalal, MD
Phone: 317-274-4505
Click here to add this to my saved trials
1475 NW 12th Ave
Miami, Florida 33136
Miami, Florida 33136
(305) 243-1000
Principal Investigator: Raja Mudad, M.D.
Phone: 305-243-0363
University of Miami, Sylvester Comprehensive Cancer Center Sylvester Comprehensive Cancer Center integrates all cancer-related activities...
Click here to add this to my saved trials
Nashville, Tennessee 37203
Principal Investigator: Melissa Johnson, MD
Phone: 615-329-7400
Click here to add this to my saved trials
Palo Alto, California 94304
Principal Investigator: Joel W Neal, MD PhD
Phone: 650-723-1002
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19111
Principal Investigator: Martin Edelman, MD
Phone: 215-728-2195
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Ramaswamy Govindan, MD
Phone: 314-286-2098
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
Click here to add this to my saved trials
Tampa, Florida 33612
Principal Investigator: Ben Creelan, MD, MS
Phone: 813-745-1344
Click here to add this to my saved trials
Toronto, Ontario
Principal Investigator: Penelope Bradbury, MD
Phone: 416-946-4501
Click here to add this to my saved trials